Search results for "Cutaneous"

showing 10 items of 1022 documents

Correlation Between Smoking Paradox and Heart Rhythm Outcomes in Patients With Coronary Artery Disease Receiving Percutaneous Coronary Intervention

2022

BackgroundThe effect of smoking on short-term outcomes among patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is controversial. However, little is known about the impact of smoking on long-term outcomes in patients with stable coronary artery disease (CAD) who receive PCI.MethodsA total of 2,044 patients with stable CAD undergoing PCI were evaluated. They were divided into two groups according to smoking status (current smokers vs. non-smokers). Baseline characteristics, exposed risk factors, angiographic findings, and interventional strategies were assessed to compare the long-term clinical outcomes between groups. Predictors for myocardial in…

long-term outcomestable coronary artery diseaseRC666-701percutaneous coronary interventionrisk factorsDiseases of the circulatory (Cardiovascular) systemsmoker's paradoxcardiovascular diseasesCardiology and Cardiovascular MedicineFrontiers in Cardiovascular Medicine
researchProduct

Application of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients.

2007

The threshold of toxicological concern (TTC) has been used for the safety assessment of packaging migrants and flavouring agents that occur in food. The approach compares the estimated oral intake with a TTC value derived from chronic oral toxicity data for structurally-related compounds. Application of the TTC approach to cosmetic ingredients and impurities requires consideration of whether route-dependent differences in first-pass metabolism could affect the applicability of TTC values derived from oral data to the topical route. The physicochemical characteristics of the chemical and the pattern of cosmetic use would affect the long-term average internal dose that is compared with the re…

media_common.quotation_subjectAdministration OralCosmeticsToxicologyAdministration CutaneousCosmeticsDecision Support TechniquesToxicologyToxicity TestsHumansPredicted no-effect concentrationcardiovascular diseasesTopical routeOral toxicitymedia_commonNo-Observed-Adverse-Effect LevelChemistrySkin sensitizationDecision TreesGeneral MedicineFragrance ingredientDermal sensitizationRisk analysis (engineering)Internal doseSafetyFood ScienceFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association
researchProduct

Global Chronic Total Occlusion Crossing Algorithm

2021

© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC By-NC-ND License (http://creativecommons.org/licenses/by-nc-nd/4)

medicine.diagnostic_testAlgoritmosbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionGlobalState of the art reviewCollateral circulationTotal occlusionPercutaneous coronary interventionCatheterChronic total occlusionCoronary OcclusionIntravascular ultrasoundOcclusionAngiographyTreatment algorithmMedicineOclusão CoronáriaCardiology and Cardiovascular MedicinebusinessAlgorithmAlgorithms
researchProduct

Manejo perioperatorio de pacientes portadores de sistemas electrónicos implantables para el control del dolor crónico

2019

medicine.diagnostic_testSpinal instrumentationbusiness.industrymedicine.medical_treatmentTranscutaneous electric nerve stimulationMagnetic resonance imagingDiathermyImplantable NeurostimulatorsElectric countershockCritical Care and Intensive Care MedicineAnesthesiology and Pain MedicineX ray computedmedicineNuclear medicinebusinessRevista Española de Anestesiología y Reanimación
researchProduct

Anti-inflammatory activity of two cucurbitacins isolated from Cayaponia tayuya roots.

2004

Fractionation of an anti-inflammatory extract from Cayaponia tayuya roots yielded two active compounds, identified as 23,24-dihydrocucurbitacin B (1) and cucurbitacin R (2). Both were evaluated for their anti-inflammatory activity on several experimental models of pain and inflammation. In addition, their cytotoxicity and effects on leukotriene B 4 (LTB 4 ) formation were evaluated in rat polymorphonuclear leukocytes. Both compounds showed activity in the following models: carrageenan-induced mouse paw oedema (1, 4 mg/kg p.o., 46% inhibition at 3 h), phospholipase A 2 -induced mouse paw oedema (2, 3 mg/kg i.p., 61% inhibition at 60 min), serotonin-induced mouse paw oedema (1 and 2, 0.5 mg/k…

medicine.drug_classLeukotriene B4Pharmaceutical ScienceAdministration OralPainPharmacologyAdministration CutaneousCarrageenanLeukotriene B4Plant RootsAnti-inflammatoryPhospholipases AAnalytical Chemistrychemistry.chemical_compoundMicePhospholipase A2Drug DiscoverymedicineLeukocytesAnimalsEdemaRats WistarPharmacologyPhospholipase AbiologyDose-Response Relationship DrugPlant ExtractsAntiglucocorticoidOrganic ChemistryAnti-Inflammatory Agents Non-SteroidalCucurbitacinsbiology.organism_classificationCayaponia tayuyaTriterpenesCarrageenanRatsCucurbitaceaePhospholipases A2Complementary and alternative medicinechemistryBiochemistryEicosanoidbiology.proteinMolecular MedicineTetradecanoylphorbol AcetateFemalePhytotherapyPlanta medica
researchProduct

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges

2020

AbstractHemophilia A (HA) and B (HB) are X-linked bleeding disorders caused by mutations in the F8 or F9 gene that result in the absence, or reduced activity, of the corresponding clotting factor. The severity of bleeding and related complications is proportional to the amount of residual circulating functional factor. The development of a safe and effective hemophilia treatment lasted several decades and has been mainly based on clotting factor replacement. Advances in the engineering and manufacturing of clotting concentrates have led to the widespread availability of extended half-life products that reduced the number of intravenous infusions needed to achieve adequate trough levels. The…

medicine.medical_specialtyAcetylgalactosamineInjections SubcutaneousLipoproteinsHemorrhage030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedHemophilia AHemophilia BSeverity of Illness IndexDisease courseFactor IX03 medical and health sciencesRoute of administrationLife Expectancy0302 clinical medicineAntibodies BispecificmedicineHumansRNA Small InterferingInfusions IntravenousIntensive care medicineFactor IXClotting factorClinical Trials as TopicFactor VIIICoagulantsbusiness.industryGenetic TherapyHematologyIntravenous InfusionsHistory 20th CenturyBlood Coagulation FactorsLaboratoriesbusiness030215 immunologymedicine.drugHämostaseologie
researchProduct

Carga de comorbilidad y beneficio de la revascularización en ancianos con síndrome coronario agudo

2021

Introduction and objectives: To evaluate the interaction between comorbidity burden and the benefits of in-hospital revascularization in elderly patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). Methods: This retrospective study included 7211 patients aged ≥ 70 years from 11 Spanish NSTEACS registries. Six comorbidities were evaluated: diabetes, peripheral artery disease, cerebrovascular disease, chronic pulmonary disease, renal failure, and anemia. A propensity score was estimated to enable an adjusted comparison of in-hospital revascularization and conservative management. The end point was 1-year all-cause mortality. Results: In total, 1090 patients (15%) died. Th…

medicine.medical_specialtyAcute coronary syndromeAnemiamedicine.medical_treatmentEnfermedad cardiovascularAncianoComorbidity030204 cardiovascular system & hematologyCardiologíaRevascularization03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansSíndrome coronario agudoRegistriesAcute Coronary SyndromePropensity ScoreStrokeAgedRetrospective Studiesbusiness.industryRetrospective cohort studyGeneral Medicinemedicine.diseaseComorbidityTreatment OutcomeRevascularización miocárdicaPropensity score matchingCardiologybusiness
researchProduct

Update on Ischemic Heart Disease and Critical Care Cardiology

2014

This article summarizes the main developments reported in 2013 on ischemic heart disease, together with the most important innovations in the management of acute cardiac patients. 3.792 JCR (2014) Q2, 34/123 Cardiac & cardiovascular systems UEM

medicine.medical_specialtyAcute coronary syndromeCritical Caremedicine.medical_treatmentEnfermedad cardiovascularMyocardial InfarctionMyocardial IschemiaDiseaseCardiologíaTratamiento médicoPercutaneous Coronary InterventionSex FactorsSex factorsInternal medicinemedicineHumansMyocardial infarctionAcute Coronary SyndromeIntensive care medicinePatofisiologíaSistema cardiovascularbusiness.industryAge FactorsPercutaneous coronary interventionGeneral Medicinemedicine.diseasePrognosisPrimary PreventionConventional PCICardiologycardiovascular systemPlatelet aggregation inhibitorInfarto de miocardiobusinessIschemic heartPlatelet Aggregation InhibitorsRevista Española de Cardiología (English Edition)
researchProduct

Coronary Revascularization and Long-Term Survivorship in Chronic Coronary Syndrome

2021

Ischemic heart disease (IHD) persists as the leading cause of death in the Western world. In recent decades, great headway has been made in reducing mortality due to IHD, based around secondary prevention. The advent of coronary revascularization techniques, first coronary artery bypass grafting (CABG) surgery in the 1960s and then percutaneous coronary intervention (PCI) in the 1970s, has represented one of the major breakthroughs in medicine during the last century. The benefit provided by these techniques, especially PCI, has been crucial in lowering mortality rates in acute coronary syndrome (ACS). However, in the setting where IHD is most prevalent, namely chronic coronary syndrome (CC…

medicine.medical_specialtyAcute coronary syndromeIschemic heart diseasemedicine.medical_treatmentstress cardiac magnetic resonancelcsh:MedicineChronic coronary syndromeReviewischemiaDisease030204 cardiovascular system & hematologyRevascularizationCoronary artery diseaseCoronary artery disease03 medical and health sciences0302 clinical medicineIschemiaInternal medicineMedicine030212 general & internal medicineCause of deathStress cardiac magnetic resonancechronic coronary syndromebusiness.industryMortality ratelcsh:RPercutaneous coronary interventionGeneral Medicinemedicine.diseaseischemic heart diseaseMyocardial revascularizationmyocardial revascularizationConventional PCICardiologybusinesscoronary artery diseaseJournal of Clinical Medicine
researchProduct

0349: Transfer of acute coronary syndrome patients in the Alps (SCA-Alpes). Data from the RESURCOR network

2016

RationaleIn France, the transfer of patients with an acute coronary syndrome (ACS) from one centre to another is usually done by SMUR, with on-board medical staff. However, SMUR is not always available. In this study from the RESURCOR network, we investigated clinical outcomes in ACS patients transferred in private ambulances without on-board medical staff.MethodIn the French Alps, the RESURCOR network arranges “SCAAlpes” transfers in private ambulances with no medical doctors on board but with non-medically trained staff who follow strict management protocols. Ambulances are equipped with an automatic external defibrillator and patients are not under heart monitoring. These transfers are f…

medicine.medical_specialtyAcute coronary syndromeMedical staffReferralbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionmedicine.diseaseHeart monitoringSudden deathConventional PCIEmergency medicinemedicineMedical emergencyMyocardial infarctionbusinessCardiology and Cardiovascular MedicineArchives of Cardiovascular Diseases Supplements
researchProduct